Current and future use of favipiravir in patients with COVID-19
There are experimental and clinical data regarding the activity of favipiravir against the SARS-CoV-2 virus. The is evidence of significant variability in pharmacokinetics and associated achievement of the required inhibitory concentration of the drug. The evidence base for the effectiveness of use...
Wedi'i Gadw mewn:
| Prif Awduron: | , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Russo |
| Cyhoeddwyd: |
Izdatelstvo OKI
2020-10-01
|
| Cyfres: | Качественная клиническая практика |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.clinvest.ru/jour/article/view/540 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|